A Phase II Trial of Sacituzumab Govitecan (TRODELVY™) (NSC #820016) for Patients with HER2-Negative Breast Cancer and Brain Metastases
Read more about this trial →← Back to available clinical trials
A Phase II Trial of Sacituzumab Govitecan (TRODELVY™) (NSC #820016) for Patients with HER2-Negative Breast Cancer and Brain Metastases
Read more about this trial →